Researcher Profile

Researcher Profile

Dawit Aregawi, MD

Dawit Aregawi, MD

Assistant Professor, Department of Neurosurgery
Scientific Program:Experimental Therapeutics
Disease Teams:
Central Nervous System Cancer
dxa22@psu.edu

Research Interests

  • Therapeutics
  • Polycystic Ovary Syndrome
  • Diet
  • Metformin
  • Glioblastoma
  • Neoplasm Metastasis
  • Pseudotumor Cerebri
  • Neoplasms
  • Thrombophilia
  • Mutation
  • Pregnancy
  • Weights and Measures

Clinical Trials

A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma
Risk Factors for CIPN Following an Oxaliplatin-Containing Chemotherapy Regimen in Colorectal Cancer Patients
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study

Recent Publications

2019

Payne, R, Mrowczynski, OD, Slagle-Webb, B, Bourcier, A, Mau, C, Aregawi, D, Madhankumar, A, Lee, SY, Harbaugh, K, Connor, J & Rizk, E 2019, 'MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors', Journal of neurosurgery, vol. 130, no. 2, pp. 465-475. https://doi.org/10.3171/2017.8.JNS17765

2017

Davis, G, Lee, M, Aregawi, D, Shaffrey, ME, Schiff, D & Sherman, JH 2017, Spinal metastasis as complication of systemic cancers. in Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment: Third Edition. Springer International Publishing, pp. 113-125. https://doi.org/10.1007/978-3-319-57901-6_6

2015

Odia, Y, Kreisl, TN, Aregawi, D, Innis, EK & Fine, HA 2015, 'A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas' Journal of neuro-oncology, vol. 125, no. 1, pp. 191-195. https://doi.org/10.1007/s11060-015-1894-y

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)